PMID: 19923892Nov 20, 2009Paper

Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads

Cell Cycle
Annamaria RapisardaGiovanni Melillo

Abstract

Novel molecularly targeted therapies aim at exploiting oncogenic and non-oncogenic alterations that epitomize potential vulnerable aspects of tumorigenesis, with the hope to ultimately target cancer cells and spare normal tissues. Hypoxia, a decrease in tissue oxygen levels, is a feature of the tumor microenvironment that has attracted considerable interest for its potential contribution to increasing the tumorigenicity of cancer cells, by selecting more aggressive and metastatic clones and by activating pathways that contribute to cancer cells survival, all of which may have important therapeutic implications. In this article, we discuss how two therapeutic strategies, which have been developed over the last few years to target aspects dependent on or associated with intratumor hypoxia, may provide the rationale for a novel combination strategy aimed at blocking compensatory circuits that maintain cancer cells survival and propagate the cancer phenotype. We hypothesized that concurrent inhibition of HIF-1 and VEGF, which are mechanistically linked to intratumor hypoxia, represents a logical therapeutic combination that may find applications in a number of solid tumors, irrespective of their underlying genetic alterations. Inde...Continue Reading

Citations

Apr 25, 2012·Nature Reviews. Clinical Oncology·Annamaria Rapisarda, Giovanni Melillo
Jul 4, 2013·Oncology Reports·Beverly A Teicher
Mar 28, 2013·Expert Opinion on Medical Diagnostics·Amin Ben LassouedJean Gabert
Mar 9, 2012·Trends in Pharmacological Sciences·Gregg L Semenza
Nov 17, 2011·Cancer·Shaad E Abdullah, Roman Perez-Soler
Apr 24, 2014·TheScientificWorldJournal·Daniela SorrientoGuido Iaccarino
Apr 22, 2015·Cell·Dong Chul LeeYoung Il Yeom
Jan 10, 2012·Aging·Zoya N Demidenko, James A McCubrey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.